Phase 2
An investigational Alzheimer’s disease drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.
Galectin Therapeutics takes its role seriously, as perhaps the only company developing a therapy for non-alcoholic steatohepatitis (NASH) cirrhosis, an advanced form of NASH. Along with its Phase IIb/III clinical trial, it recently launched NAVIGATEnash.com.
Sanofi will use its manufacturing capabilities to support the development of 200 million doses of the Moderna COVID-19 vaccine beginning in September.
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here’s a look.
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.
The agency is requesting additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.
A Phase II schizophrenia treatment is showing promise for patients diagnosed with this complex and chronic brain disorder.
PRESS RELEASES